Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7243 results

Sort By:

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Study ID: NCT06131801
Start Date: 2023-11-15
End Date: 2027-12-01
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment

1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.

Sponsor

Children's Hospital Medical Center, Cincinnati

Source: clinicaltrials.gov

Share:
Add to list

A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma

Study ID: NCT04139304
Start Date: 2021-05-24
End Date: 2030-07
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

15

Intervention / Treatment

Cyclophosphamide

DARATUMUMAB

Doxorubicin

Doxorubicin Hydrochloride

Etoposide

Prednisone

Vincristine

Vincristine Sulfate

Sponsor

AIDS Malignancy Consortium

Source: clinicaltrials.gov

Share:
Add to list

The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy

Study ID: NCT05688904
Start Date: 2023-01-19
End Date: 2028-03
Study Type

Interventional

Study Phase

Phase1

No. of Participants

24

Intervention / Treatment

Imipramine

Vehicle

Sponsor

Wright State University

Source: clinicaltrials.gov

Share:
Add to list

IDENTIFY Study: Natural History of Maternal Neoplasia

Study ID: NCT04049604
Start Date: 2019-12-23
End Date: 2029-04-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

320

Intervention / Treatment
Sponsor

National Human Genome Research Institute (NHGRI)

Source: clinicaltrials.gov

Share:
Add to list

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Study ID: NCT05691504
Start Date: 2023-09-14
End Date: 2027-02-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

42

Intervention / Treatment

Biopsy Procedure

Biospecimen Collection

Cobiet

Computed Tomography

Echocardiography Test

Magnetic Resonance Imaging

Multigated Acquisition Scan

Pelcitoclax

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors

Study ID: NCT05687604
Start Date: 2024-09-24
End Date: 2027-07-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

1500

Intervention / Treatment

multiple behavior change therapy

Sponsor

Northwestern University

Source: clinicaltrials.gov

Share:
Add to list

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Study ID: NCT05255601
Start Date: 2022-09-13
End Date: 2028-07-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

68

Intervention / Treatment

Relatylimab

Nivolumab

Sponsor

Bristol-Myers Squibb

Source: clinicaltrials.gov

Share:
Add to list

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

Study ID: NCT02279004
Start Date: 2014-07-03
End Date: 2026-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

840

Intervention / Treatment
Sponsor

Dana-Farber Cancer Institute

Source: clinicaltrials.gov

Share:
Add to list

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma

Study ID: NCT02021604
Start Date: 2013-10-09
End Date: 2028-06
Study Type

Interventional

Study Phase

Phase1

No. of Participants

250

Intervention / Treatment

Fluorodopa F 18

Sponsor

Cook Children's Health Care System

Source: clinicaltrials.gov

Share:
Add to list

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Study ID: NCT06952504
Start Date: 2025-05-22
End Date: 2032-05-24
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1123

Intervention / Treatment

Pembrolizumab

Carboplatin

Paclitaxel

Docetaxel

Sacituzumab Tirumotecan

Sponsor

Merck Sharp & Dohme LLC

Source: clinicaltrials.gov

Share:
Add to list